MECP2 and Rett syndrome: We sought to characterize gastrointestinal and metabolic molecular signatures of RTT disease progression at the gut-brain interface by simultaneously evaluating the fecal microbiome and metabolome longitudinally across symptom progression in a construct-relevant mouse model of RTT, that leverages an Mecp2-e1 isoform-specific knock-in mutation found in human RTT patients38,40.